Damora Therapeutics Financial Statements
NASDAQ: DMRAHealthcareBiotechnologyUSD
21.08+0.52 (+2.53%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Damora Therapeutics revenue and earnings
Damora Therapeutics reported a net loss of $209.8 million, compared with a loss of $21.4 million a year earlier. Diluted earnings per share came in at $3.98.
Summary generated from market data by MetaCap's automated system. Methodology
Damora Therapeutics income statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 |
|---|---|---|---|---|---|---|---|
| Operating Expenses | 210.87M | 22.26M | 39.91M | 61.21M | 52.23M | 33.64M | 38.97M |
| Research & Development | 26.88M | 6.40M | 23.77M | 48.21M | 38.49M | 24.63M | 19.74M |
| Operating Income | -210.87M | -22.26M | -39.91M | -61.21M | -52.23M | -33.64M | 38.97M |
| Other Income (Expense) | 1.08M | 862.00K | 1.56M | -417.00K | 475.00K | -1.20M | 2.46M |
| Pretax Income | -209.79M | -21.40M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M |
| Income Tax | 50.00K | 41.00K | 0 | 0 | 0 | 0 | 0 |
| Net Income | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| EPS (Basic) | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 | -7.62 | -161.82 |
| EPS (Diluted) | 3.98 | -18.53 | -36.08 | -2.43 | -2.05 | -7.62 | -161.82 |
| Shares Outstanding (Basic) | 1.36M | 1.16M | 1.06M | 25.41M | 25.26M | 4.57M | 259.97K |
| Shares Outstanding (Diluted) | 1.36M | 1.16M | 1.06M | 25.41M | 25.26M | 4.57M | 259.97K |
| EBITDA | -210.85M | -22.24M | -39.64M | -61.16M | -52.21M | — | — |
This table shows 7 annual periods of Damora Therapeutics's income statement, from FY 2025 back to FY 2019, across 12 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow DMRA's reporting calendar. What is a income statement?